Advertisement

NLS Verrica

Agreement - August 12, 2020

Lytix Biopharma enters milestone agreement

Lytix Biopharma licenses its lead candidate LTX-315, an oncolytic peptide based immunotherapy, to Verrica Pharmaceuticals, for the treatment of dermatologic oncology indications. “With aggregate payments of more than $110M” Lytix is entitled to receive an up-front payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of more […]

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.